A Randomized, Two-Cohort Phase II Study of Two Doses of BMS-275183 Given on a Weekly Schedule in Patients With Pre-Treated Non-Small Cell Lung Cancer
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Non-small Cell Lung Cancer
Both
Non-small Cell Lung Cancer
Trial Information
A Randomized, Two-Cohort Phase II Study of Two Doses of BMS-275183 Given on a Weekly Schedule in Patients With Pre-Treated Non-Small Cell Lung Cancer
Inclusion Criteria:
- Advanced or metastatic pretreated NSCLC
- Measurable disease
- Adequate hematologic, hepatic and renal functions
- ECOG Performance Status of 0-2
Exclusion Criteria:
- Inability to swallow capsules
- Recent significant cardiovascular disease
- Woman who are pregnant or breastfeeding
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Authority:
United States: Food and Drug Administration
Study ID:
CA165-020
NCT ID:
NCT00099879
Start Date:
Completion Date:
Related Keywords:
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|---|
| Local Institution | Chicago, Illinois |
| Local Institution | Corona, California |
| Local Institution | Hamden, Connecticut |
| Local Institution | Duncansville, Pennsylvania |
| Local Institution | Rome, Georgia |
| Local Institution | Chattanooga, Tennessee |
| Local Institution | Detroit, Michigan |
